Researchers are racing to develop a test that shows how long COVID-19 vaccines work

Researchers urgently want to know how long the current crop of effective COVID-19 vaccines protect against infection and also would like a quicker and more efficient way to test the efficacy of new vaccines. They are trying to check both of those boxes by studying antibody levels in people already exposed to the new coronavirus.
A study at Oxford University is deliberately exposing previously infected healthy young volunteers to the coronavirus again, using blood tests to learn what level of antibodies will protect people against getting sick again. "It may be not possible to reinfect with an antibody level above a certain amount," lead investigator Helen McShane told NPR News. When researchers find that level of antibodies — or antibody cutoff titer — they can develop blood tests to determine how long vaccines are effective.
A separate study involving the U.S. government's Biomedical Advanced Research and Development Authority (BARDA), the Fred Hutchinson Cancer Research Center, and Moderna is also trying to find the cutoff titer by examining antibodies in people who got COVID-19 symptoms after getting inoculated with Moderna's vaccine. "Because the Moderna vaccine is so very effective, it's taken a very long time to collect enough from the vaccinated individuals who became infected," BARDA's Chris Houchens tells NPR. Now that they have data from enough people, they should soon be able to calculate whether a certain level of antibodies can show that new vaccines are effective without having to test the vaccines on tens of thousands of people. You can listen to NPR's report below. Peter Weber
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Classic car insurance: how best to protect your vintage vehicle
The Explainer Insuring your classic car may be cheaper than you think
By Marc Shoffman, The Week UK Published
-
Celebrating 250 years of Jane Austen
The Week Recommends From exhibitions to Regency balls, these are the best ways to commemorate the author
By Irenie Forshaw, The Week UK Published
-
The pressure of South Korea's celebrity culture
In The Spotlight South Korean actress Kim Sae-ron was laid to rest on Wednesday after an apparent suicide
By Abby Wilson Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published